Prophylaxis News and Research RSS Feed - Prophylaxis News and Research

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease. [More]
University of Granada researchers patent new treatment for acne

University of Granada researchers patent new treatment for acne

University of Granada scientists have patented a new treatment for acne that is based on completely natural substances and is much more effective than artificial formulas because it does not create resistance to bacteria and has no secondary effects. [More]

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Biogen Idec announced today that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for the marketing approval of ELOCTATE (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A. [More]

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery. [More]

New rationale for treating patients with cirrhosis and portal hypertension

New data from clinical studies presented for the first time at the International Liver Congress- 2013 provide new rationale for an old and established treatment option for portal hypertension. [More]

Research shows probiotics reduce the development of hepatic encephalopathy

Probiotics could emerge as a treatment plan to manage hepatic encephalopathy (HE) therapy after a new study announced at the International Liver Congress- 2013 found they significantly reduced development of the notoriously difficult-to-treat disease. [More]
Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor. [More]
BD receives FDA approval for second prefilled injectable drug

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables. [More]
New assays are effective in managing patients with influenza virus infection

New assays are effective in managing patients with influenza virus infection

Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly. [More]
Study shows mathematical models can help assess effectiveness of HIV intervention combinations

Study shows mathematical models can help assess effectiveness of HIV intervention combinations

South Africa is home to the largest HIV epidemic in the world with a total of 5.6 million people living with HIV. Large-scale clinical trials evaluating combination methods of prevention and treatment are often prohibitively expensive and take years to complete. [More]

Study: Using best-practice approach could lead to big cost reductions in hospitals nationwide

A major challenge facing today's health care community is to find ways to lower costs without compromising clinical quality. Taking that challenge to task, researchers at Medstar Health and Georgetown University School of Medicine, Washington DC, report success in using a concept called "value-based analysis," which simultaneously measures quality and cost and addresses inefficiencies in care. [More]
FDA accepts Merck's NDA for NOXAFIL tablets

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration. [More]
New study suggests that Ranibizumab can be potential prophylaxis for PVR

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Proliferative vitreoretinopathy, or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life. [More]
Research shows immune system can destroy HIV through deactivation of vif gene

Research shows immune system can destroy HIV through deactivation of vif gene

Human cells have an intrinsic capacity to destroy HIV. However, the virus has evolved to contain a gene that blocks this ability. When this gene is removed from the virus, the innate human immune system destroys HIV by mutating it to the point where it can no longer survive. [More]
POZEN announces submission of NDA for marketing approval of PA32540/PA8140

POZEN announces submission of NDA for marketing approval of PA32540/PA8140

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140. [More]
Dialysis patients face increased risk of antibiotic-resistant infections

Dialysis patients face increased risk of antibiotic-resistant infections

Patients who receive hemodialysis are at a significant risk of developing infections, a leading cause of hospitalization and death in this patient population. [More]

Listen to women's needs when designing HIV prevention strategies

According to "results from a large HIV prevention trial among African women" known as VOICE and released last week, "none of the prevention methods tested in the study made a difference in HIV infection rates, because few women actually used them as directed," AVAC Executive Director Mitchell Warren writes in an opinion piece published in the Huffington Post's "Global Motherhood" blog. [More]
Weight loss may help prevent and alleviate symptoms of osteoarthritis

Weight loss may help prevent and alleviate symptoms of osteoarthritis

Weight loss may prevent and significantly alleviate the symptoms of osteoarthritis, a progressive disease of the joints known as "wear and tear" arthritis, according to a literature review appearing in the March 2013 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS). [More]
Antibiotic prophylaxis after IVT may be harmful

Antibiotic prophylaxis after IVT may be harmful

Researchers are warning against routine antibiotic prophylaxis with intravitreal injection after finding that the practice can increase the antibiotic resistance of ocular surface flora. [More]
AHRQ releases Making Health Care Safer II report

AHRQ releases Making Health Care Safer II report

The Agency for Healthcare Research and Quality (AHRQ) has released a new report, Making Health Care Safer II, which identifies the top 10, evidence-based patient safety strategies available to clinicians. [More]